Johnson & Johnson (NYSE:JNJ) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company’s blockbuster psoriasis treatment.

Johnson & Johnson (NYSE:JNJ) reported its third-quarter 2024 earnings, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $2.04, slightly above the forecasted $2.02. The ...